ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling



Summary

This study explores the predictive power of the Immune Cell-Associated Neurotoxicity Syndrome (ICANS) risk model in CD19 CAR-T therapy patients by analyzing serum and cerebrospinal fluid (CSF) cytokine profiles. The research found that the ICANS risk model can effectively identify patients at higher risk of developing neurotoxicity. Furthermore, distinct cytokine patterns in both serum and CSF were associated with varying ICANS severity levels, offering insights into the underlying inflammatory mechanisms. The analysis suggests that specific cytokines could potentially serve as biomarkers for early detection and management of ICANS, potentially leading to improved patient outcomes following CAR-T cell therapy.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!